Literature DB >> 9026365

Brain monoaminergic and neuropeptidergic variations in human aging.

B Arranz1, K Blennow, R Ekman, A Eriksson, J E Månsson, J Marcusson.   

Abstract

The effect of age on the monoamines 5-hydroxytryptamine (5-HT), noradrenaline (NA) and dopamine (DA), their metabolites 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), 3,4-dihydroxphenylacetic acid (DOPAC), and the 5-HT precursor 5-hydroxy-L-tryptophan (5-HTP), together with the peptides neuropeptide Y (NPY), somatostatin (SOM), and corticotropin-releasing factor (CRF), was studied in frontal cortex, gyrus cinguli and hypothalamus from 23 healthy control subjects, aged 16-75 years. After correcting for postmortem interval, significant decreases in gyrus cinguli NA, NPY and CRF, and hypothalamic DA, HVA, and 5-HIAA concentrations were obtained with advancing age. The involvement of the monoaminergic system in several functional abnormalities appearing in senescence is suggested. Furthermore, evidence is given of the participation of the peptidergic systems in the aging process.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9026365     DOI: 10.1007/BF01292620

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  61 in total

1.  Age stability of human brain 5-HT terminals studied with [3H]paroxetine binding.

Authors:  A Andersson; I Sundman; J Marcusson
Journal:  Gerontology       Date:  1992       Impact factor: 5.140

2.  Neocortical cell counts in normal human adult aging.

Authors:  R D Terry; R DeTeresa; L A Hansen
Journal:  Ann Neurol       Date:  1987-06       Impact factor: 10.422

3.  Determination of 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and homovanillic acid in brain tissue from an autopsy material.

Authors:  C G Gottfries; B E Roos; B Winblad
Journal:  Acta Psychiatr Scand       Date:  1974       Impact factor: 6.392

Review 4.  Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature.

Authors:  G R Martin; P P Humphrey
Journal:  Neuropharmacology       Date:  1994 Mar-Apr       Impact factor: 5.250

5.  Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes.

Authors:  E K Perry; G Blessed; B E Tomlinson; R H Perry; T J Crow; A J Cross; G J Dockray; R Dimaline; A Arregui
Journal:  Neurobiol Aging       Date:  1981       Impact factor: 4.673

6.  Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease.

Authors:  E B De Souza; P J Whitehouse; M J Kuhar; D L Price; W W Vale
Journal:  Nature       Date:  1986 Feb 13-19       Impact factor: 49.962

7.  Monoamine metabolism in human brain.

Authors:  D S Robinson; T L Sourkes; A Nies; L S Harris; S Spector; D L Bartlett; I S Kaye
Journal:  Arch Gen Psychiatry       Date:  1977-01

8.  Memory function and brain biochemistry in normal aging and in senile dementia.

Authors:  B Winblad; J Hardy; L Bäckman; L G Nilsson
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

Review 9.  Neuropeptide Y (NPY) and the central nervous system: distribution effects and possible relationship to neurological and psychiatric disorders.

Authors:  C Wahlestedt; R Ekman; E Widerlöv
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1989       Impact factor: 5.067

10.  The effect of neuropeptide Y on striatal catecholamines.

Authors:  M F Beal; R C Frank; D W Ellison; J B Martin
Journal:  Neurosci Lett       Date:  1986-10-30       Impact factor: 3.046

View more
  3 in total

1.  Oxidative stress in the progression of Alzheimer disease in the frontal cortex.

Authors:  Mubeen A Ansari; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2010-02       Impact factor: 3.685

Review 2.  Astroglia in Alzheimer's Disease.

Authors:  Alexei Verkhratsky; Vladimir Parpura; Jose Julio Rodriguez-Arellano; Robert Zorec
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

3.  Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.

Authors:  F S Hall; K Itokawa; A Schmitt; R Moessner; I Sora; K P Lesch; G R Uhl
Journal:  Neuropharmacology       Date:  2013-08-24       Impact factor: 5.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.